131 related articles for article (PubMed ID: 21216276)
1. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia.
Kitawaki T; Kadowaki N; Fukunaga K; Kasai Y; Maekawa T; Ohmori K; Itoh T; Shimizu A; Kuzushima K; Kondo T; Ishikawa T; Uchiyama T
Exp Hematol; 2011 Apr; 39(4):424-433.e2. PubMed ID: 21216276
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
[TBL] [Abstract][Full Text] [Related]
3. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
[TBL] [Abstract][Full Text] [Related]
4. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
[TBL] [Abstract][Full Text] [Related]
5. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
[TBL] [Abstract][Full Text] [Related]
6. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
[TBL] [Abstract][Full Text] [Related]
7. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
8. [T-cell immunity against autologous leukemic cell mediated by in vitro bone marrow-derived dendritic cell from patients with acute myeloid leukemia in complete remission].
He X; You S; Bian S
Zhonghua Xue Ye Xue Za Zhi; 2001 Dec; 22(12):629-32. PubMed ID: 16200709
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches].
Mohty M; Gaugler B; Calmels B; Blaise D; Vey N; Chabannon C; Olive D
Bull Cancer; 2003; 90(8-9):751-7. PubMed ID: 14609765
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation.
Lee JJ; Kook H; Park MS; Nam JH; Choi BH; Song WH; Park KS; Lee IK; Chung IJ; Hwang TJ; Kim HJ
J Clin Apher; 2004; 19(2):66-70. PubMed ID: 15274198
[TBL] [Abstract][Full Text] [Related]
11. [Induction of co-stimulatory molecules on the surface of blast cells in patients with acute myeloid leukemia].
Sadovnikova EIu; Strel'nikova TB; Parovichnikova EN; Savchenko VG
Ter Arkh; 2001; 73(7):34-40. PubMed ID: 11523406
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.
Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Immunobiology; 2006; 211(6-8):677-85. PubMed ID: 16920506
[TBL] [Abstract][Full Text] [Related]
14. [The induction of the antitumor activity of T-lymphocytes by antigen-presenting cells obtained from the blast cells of patients with acute leukemias].
Savchenko VG; Sadovnikova EIu; Parovichnikova EN; Mendeleeva LP; Demidova IA; Sokolov AN; Isaev VG
Ter Arkh; 2000; 72(7):14-21. PubMed ID: 10983315
[TBL] [Abstract][Full Text] [Related]
15. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.
Houtenbos I; Westers TM; Dijkhuis A; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
Clin Cancer Res; 2007 Jan; 13(1):307-15. PubMed ID: 17170077
[TBL] [Abstract][Full Text] [Related]
16. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.
Zhong RK; Lane TA; Ball ED
Exp Hematol; 2008 Apr; 36(4):486-94. PubMed ID: 18249062
[TBL] [Abstract][Full Text] [Related]
17. The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity.
Houtenbos I; Santegoets S; Westers TM; Waisfisz Q; Kipriyanov S; Denkers F; Scheper RJ; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2008 Jun; 142(2):273-83. PubMed ID: 18492117
[TBL] [Abstract][Full Text] [Related]
18. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia.
Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Biomed Pharmacother; 2007 Jul; 61(6):306-14. PubMed ID: 17368821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
